Syngene reported revenue growth of 11% year-on-year, and 8% sequentially crossing the Rs. 1,000 Cr in a quarter threshold for the first time
The company delivered revenues of Rs. 5,554 crore, representing 10% growth in FY25
The National IP Awards recognize outstanding contributions to India’s innovation economy through effective IP creation and commercialization
The company does not expect this development to have any material impact on the current business operations
Raichur site is the group’s largest API facility and part of a wider network of seven sites
L-HPC was independently developed by Shin-Etsu Chemical as a disintegrant for tablets
AstraZeneca Pharma India discontinues manufacturing of Imdur
The inspection has concluded with four observations
Alembic Pharmaceuticals successfully completes USFDA inspection for API-III facility
The inspection, conducted from March 17 to March 21, 2025, concluded with one observation in Form 483
Subscribe To Our Newsletter & Stay Updated
